Sex hormones contribute to sex differences in blood pressure. Inappropriate activation of the renin-angiotensin system is involved in vascular dysfunction and hypertension. This study evaluated the role of androgens (testosterone) in angiotensin II (Ang II)-induced increase in blood pressure, vascular reactivity, and cardiac hypertrophy. Eight-week-old male Wistar rats underwent sham operation, castration, or castration with testosterone replacement. After 12 weeks of chronic changes in androgen status, Ang II (120 ng/kg per minute) or saline was infused for 28 days via subcutaneous miniosmotic pump, and changes in blood pressure was measured. Vascular reactivity and Ang II receptor levels were examined in mesenteric arteries. Heart weight, cardiac ANP mRNA levels, and fibrosis were also assessed. Ang II infusion increased arterial pressure in intact males. The Ang II-induced increase in hypertensive response was prevented in castrated males. Testosterone replacement in castrated males restored Ang II-induced hypertensive responses. Castration reduced vascular AT 1 R/AT 2 R ratio, an effect that was reversed by testosterone replacement. Ang II-induced hypertension was associated with increased contractile response of mesenteric arteries to Ang II and phenylephrine in intact and testosterone-replaced castrated males; these increases were prevented in castrated males. Ang II infusion induced increased left ventricle-to-body weight ratio and ANP mRNA expression, indicators of left ventricular hypertrophy, and fibrosis in intact and testosterone-replaced castrated males, and castration prevented the increase in these parameters caused by Ang II. This study demonstrates that testosterone plays a permissive role in development and maintenance of Ang II-induced vascular dysfunction, hypertension, and cardiac hypertrophy. Mishra et al., 2019, Vol. 100, No. 1 
Introduction
Cardiovascular diseases (CVD) are the leading cause of mortality and morbidity in the United States. Among CVD, hypertension ranks first, affecting more than 75 million people-nearly 1 in 3 adults (Center for Disease Control statistics, 2017). Epidemiological and clinical studies have demonstrated a role for sex-dependent mechanisms in the pathophysiology of hypertension and cardiac hypertrophy. For example, the incidence and severity of hypertension have been shown to be greater in men than age matched premenopausal women [1, 2] . Also, sex differences in hypertension and cardiac hypertrophy have been demonstrated in both genetic and induced models, including Dahl salt-sensitive rats [3] , deoxycorticosterone acetate hypertension [4] , spontaneously hypertensive rats [5] , one-kidney renal wrap hypertension [6] , and in utero programmed hypertension [7] [8] [9] [10] . In these animals, hypertension developed more rapidly and severely in male compared to female rats. Also, orchiectomy prevented blood pressure elevation and testosterone replacement restored hypertension in males. In the females, ovariectomy increased blood pressure and estrogen replacement attenuated this increase. These studies suggest that sex hormones participate in hypertension development, with testosterone exacerbating blood pressure in males and estrogen protecting against blood pressure increase in females. Although numerous studies have examined the protective mechanisms of estrogens on cardiovascular function, few studies have examined how androgens contribute for cardiovascular pathology.
Among the various regulatory systems that impact blood pressure and cardiac function, the renin-angiotensin system (RAS) has a key role. Inappropriate activation of RAS leads to profound hypertension and cardiovascular morbidity [11, 12] . Angiotensin II (Ang II), the main effector of RAS, is increased in patients and animal models of hypertension and cardiac hypertrophy [13, 14] . At the cellular level, responsiveness to Ang II is conferred by the expression of the two classes of angiotensin receptors (AT 1 R and AT 2 R). These receptors are expressed in a variety of tissues, including the heart and vasculature [15] , and RAS blockade, especially AT 1 R, effectively reduces blood pressure and ameliorate cardiovascular complications [16, 17] , suggesting that dysregulation of the RAS contributes to their pathophysiology.
Studies in humans and hypertensive animal models have demonstrated the importance of interaction between testosterone and RAS in regulating cardiovascular function and blood pressure [18, 19] . Much evidence supports that males have greater expression of classical RAS components Ang II and AT 1 R and lower levels of AT 2 R [20, 21] . Androgens augment renal vascular responses to Ang II in New Zealand genetically hypertensive rats [22] . However, the functional impact of androgens in Ang II-induced hypertension and cardiac hypertrophy has given seemingly contradictory information. Some studies have shown that androgens protect against Ang II-induced cardiovascular dysfunction [23] [24] [25] , while others demonstrated that testosterone enhance the cardiovascular detrimental effects of Ang II [22, [26] [27] [28] . Our and other recent studies show that Ang II-induced vascular contraction depends on androgen status, with elevated androgen levels contributing for exaggerated vasoconstriction in in utero programmed hypertension [29] [30] [31] . This led us to hypothesize that androgens contribute to Ang II-induced hypertension and cardiac hypertrophy. Studies in men show that testosterone supplements improve libido, protect against osteoporosis, and improve overall feelings of well-being [32, 33] ; however, no long-term studies have carefully documented the cardiovascular consequences of chronic androgen changes in men. Hence, we determined whether chronic changes in the androgen environment could induce alterations in Ang II-induced hypertension, vascular reactivity, and cardiac hypertrophy in intact, castrated and testosterone-replaced castrated male rats. The results show that Ang II-induced increase in blood pressure and associated cardiac pathophysiological changes, including hypertrophy and fibrosis were minimized by castration, and reversed by testosterone replacement. These findings indicate that testosterone plays a permissive role in Ang II-induced hypertension and associated cardiac effects.
Methods

Animals
All experiments were carried out according to the protocols approved by our Institutional Animal Care and Use Committee in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Eight-week-old male Wistar rats were purchased from Charles River Laboratories (Houston, TX). Since male rats reach sexually maturity and have stable testosterone levels after 6-7 weeks of age, we used 8-week-old post pubertal rats for this study. After 1-week acclimatization, rats were divided into three groups: (a) intact (sham operated), (b) castrated, and (c) castrated with testosterone replacement using subcutaneous implanted pellets (150 mg, 150-day release, Innovative Research of America, Sarasota, FL) [20] . Castration was done by standard procedure as described previously [8] . Rats were housed in a temperature-controlled room (23
• C) with a 12:12-hour light/dark cycle with food and water available ad libitum.
Ang II infusion and blood pressure measurement
After 12 weeks of chronic changes in androgen status, rats in the three groups were implanted with subcutaneous osmotic pumps (Alzet, Cupertino, CA) to infuse Ang II (120 ng/kg/min, n = 6 in each group) or saline (vehicle, n = 6 in each group) for 28 days. Blood pressure was measured every fourth day using a noninvasive tail cuff method (Kent Scientific, Torrington, CT) as described previously [20] . Prior to implanting the osmotic pumps, rats were acclimated to the blood pressure measuring device for 1 week. After completing infusion of Ang II or its vehicle from above treatment groups, rats were weighed and then sacrificed by CO 2 inhalation. Blood was collected to determine plasma testosterone levels, mesenteric arteries were isolated and a portion of it was processed for western blotting and the reminder was used for wire myography. The hearts were removed for hypertrophic measurements. 25 , and glucose 11.1. Studies were done in endothelium-denuded mesenteric arterial rings. Endothelium was removed by gently rubbing the intimal surface of rings with a tungsten wire. Endothelium removal was verified by the absence of relaxation to acetylcholine (10 μM) in rings precontracted with phenylephrine (3 μM). The rings were allowed to equilibrate in Krebs solution for 1 h at a resting tension. After stabilization, the rings were normalized to an internal diameter of 0.9 of L 13.3kPa using a normalization software package (Myodata; Danish Myotechnologies). Doseresponse curves were constructed using cumulative doses of Ang II (3 × 10 −11 to 3 × 10 −8 M; Sigma) and phenylephrine (10 −9 to 10 −5 M; Sigma).
Measurement of left ventricular hypertrophy Left ventricle:body weight ratio
The hearts were removed and left ventricle was separated and weighted. The ratio of left ventricle (mg) to body weight (g) was calculated and used as a measure of left ventriclar hypertrophy.
Quantification of Left Ventricular ANP mRNA Expression
Left ventricular tissues were processed for the total RNA extraction (TRIZOL, Invitrogen, Carlsbad, CA). All RNA isolates were made DNA-free by treatment with DNAse and further purified with RNeasy clean up kit (QIAGEN Inc, Valencia, CA). Total RNA concentration and integrity were determined using an ND-1000 Nanodrop spectrophotometer (Thermo Fisher Scientific, Newark, DE). One microgram of total RNA was reverse transcribed using a modified Maloney murine leukemia virus-derived RT (New England Biolabs Inc, Ipswich, MA) and a blend of oligo (dT) and random hexamer primers (Invitrogen). The reaction was carried out at 28 Results were calculated using the 2 − CT method and expressed in fold increase/decrease of the gene of interest in intact, castrated and testosterone-replaced with and without Ang II infusion. All reactions were performed in duplicate, and GAPDH was used as an internal control. TaqMan assays were done in 10 μL volume for real-time PCR at a final concentration of 250 nM TaqMan probe and 900 nM of each primer; Assays-on-Demand for atrial natriuretic peptide (ANP) (Rn00664637 g1) were obtained from Applied Biosystems.
Histopathologic Analysis
Left ventricular tissues were washed in phosphate-buffered saline, fixed overnight in 4% paraformaldehyde, and embedded in paraffin, cut into 5-μm sections, and stained with Masson trichrome as described previously [34] . Fibrosis areas within sections were measured by investigators blinded to treatment, by visualizing blue-stained areas, exclusive of staining that colocalized with perivascular or intramural vascular structures, the endocardium, or LV trabeculae. Using ImageJ software, blue-stained areas and nonstained myocyte areas from each section were determined using color-based thresholding [35] . The percentage of total fibrosis area was calculated as the summed blue-stained areas divided by total ventricular area, as described previously [36] .
Statistical analysis
For the comparison, analysis was performed using 2 × 3 ANOVA model in which the factors were treatment (Ang II and vehicle exposure) and gonadal status (intact, castration, and castration with testosterone replacement) and used contrasts to make pairwise comparisons. Cumulative concentration-response curves were analyzed by computer fitting to a 4-parameter sigmoid curve using the Prism 6 program (GraphPad, San Diego, CA) to evaluate pD 2 (negative log molar concentration for half-maximal effect) and E max (maximum asymptote of the curve). All values are expressed as means ± SE. A P < 0 .05 was considered significant. Plasma testosterone levels. Plasma testosterone levels were measured using ELISA in intact (sham-operated), castrated, and testosteronereplaced castrated males. Blood was collected following CO2 inhalation. * P < 0.05 compared with intact gonad. # P < 0.05 compared to castrated group.
All data are expressed as means ± SEM. CAS-castrated, CAS+T-castrated with testosterone replacement.
Results
Plasma testosterone levels in rats
Testosterone levels were markedly reduced following castration (n = 6; P < 0.05) compared with their intact counterparts (n = 6; Figure 1 ). Testosterone replacement reinstated plasma testosterone levels in castrated rats (n = 6; P < 0.05) similar to levels in intact males ( Figure 1 ).
Castration counteracts the hypertensive effect of Ang II in rats
Ang II infusion increased blood pressure in males with intact testes (152 ± 3 mm Hg; mean increase of 29 mm Hg; n = 6; P < 0.05; Figure 2 ). Castration alone did not alter blood pressure but prevented Ang II-induced increase in blood pressure (113 ± 2 mmHg; n = 6; mean decrease of 4 mmHg) ( Figure 2 ). Testosterone replacement in castrated males restored the ability of Ang II to increase arterial pressure to levels not different from those observed in intact males (156 ± 3 mmHg; mean increase of 28 mmHg; n = 6; P < 0.05; Figure 2 ).
Castration prevents increased AT 1 R/AT 2 R ratio in the mesenteric arteries of Ang II-treated rats
Since Ang II mediates effect through its receptors, we determined whether mesenteric arterial AT 1 R and AT 2 R expression were altered in response to Ang II infusion and castration. Ang II infusion significantly increased mesenteric arterial AT 1 R levels in intact males (35% increase; n = 6; P < 0.05; Figure 3 ). Castration significantly decreased AT 1 R (40% decrease; n = 6; P < 0.05) compared to intact males (Figure 3 ). Ang II infusion to these castrated rats minimized the increase in AT 1 R (20% increase, n = 6; P < 0.05; Figure  3 ). Testosterone replacement in castrated males restored AT 1 R, and Ang II infusion increased AT 1 R to levels similar to that in intact males (35% increase, n = 6; P < 0.05; Figure 3 ). Ang II infusion increased AT 2 R levels in intact males (100% increase; n = 6 each; P < 0.05; Figure 3) . While castration by itself significantly increased AT 2 R (160% increase; n = 6; P < 0.05), Ang II further increased AT 2 R levels (29% increase; n = 6; P < 0.05; Figure 3 ). Testosterone replacement restored AT 2 R levels, and Ang II infusion increased AT 2 R levels (53% increase; n = 6; P < 0.05) comparable to that in intact males (Figure 3) .
The AT 1 R/AT 2 R ratio was higher in the intact males, decreased by castration (75% decrease, n = 6; P < 0.05), and restored by testosterone replacement (Figure 3 ). Ang II infusion did not significantly affect this ratio in these groups (Figure 3 ).
Castration did not alter androgen receptor levels in the mesenteric arteries of Ang II-treated rats Androgen receptor levels were not significantly altered in intact, intact + Ang II, castration, castration + Ang II, testosterone replacement, or testosterone replacement + Ang II groups (Figure 4) .
Castration prevents increased vascular reactivity in Ang II-treated rats
We reasoned that activation of Ang II in the vasculature might cause hypertension by influencing peripheral vascular resistance. Therefore, we compared vascular reactivity of resistance-sized mesenteric arteries between the experimental groups. Mesenteric arteries isolated from Ang II infused intact males exhibited exaggerated vasoconstriction to ex vivo Ang II (E max : 93 ± 3.5 vs 81 ± 3.5 %; pD 2 : 8.9 ± 0.08 vs 9.1 ± 0.08 in vehicle infused intact males, n = 6; P < 0.05; Figure 5A ). In contrast, arteries from castration rats showed no evidence of exaggerated Ang II contractile response in castrated males (E max : 56 ± 6.1 vs 61 ± 1.5 %; pD 2 : 8.6 ± 0.06 vs 8.5 ± 0.09 in vehicle infused castrated males, n = 6; Figure 5A ). Castration alone attenuated contractile response to ex vivo Ang II when compared to intact males. In testosterone-replaced castrated males, Ang II infusion restored the ability of ex vivo Ang II to induce exaggerated vasoconstriction (E max : 98 ± 3.3 vs 84 ± 5.9 %; pD 2 : 9.0 ± 0.06 vs 8.7 ± 0.13 in vehicle infused testosterone-replaced castrated males, n = 6; P < 0.05) identical to that in the intact group ( Figure 5A ).
Ang II infusion in intact males significantly increased phenylephrine-induced contractile response (pD 2 : 6.7 ± 0.08 vs 6.3 ± 0.10; n = 6; P < 0.05; Figure 5B ). In contrast, in the castrated group, there was no increase in phenylephrine-induced contractile response after Ang II infusion (pD 2 : 6.1 ± 0.09 vs 6.3 ± 0.04, n = 6; Figure 5B ). In testosterone-replaced castrated males, Ang II infusion reinstated the ability of phenylephrine to induce increased vasoconstriction (pD 2 : 6.9 ± 0.06 vs 6.49 ± 0.03, n = 6; P < 0.05; Figure 5B ). There was no difference in E max for phenylephrine between respective vehicle and Ang II infusion in all groups. These results indicate that Ang II infusion leads to exaggerated vasoconstriction to Ang II and phenylephrine in mesenteric arteries of intact males, which was prevented by castration and restored by testosterone replacement.
Castration protects against cardiac hypertrophy and fibrosis in Ang II-treated rats
In patients with hypertension, one of the early and most common consequences of chronic hypertension is left ventricular hypertrophy [37, 38] . Clinical evidence suggests that the RAS contributes to the development of left ventricular hypertrophy in hypertension [39, 40] . Accordingly, we compared left ventricular weights in all the experimental groups. With Ang II infusion, the intact males developed ventricular hypertrophy as indicated by increased left ventricle-body weight ratio (n = 6; P < 0.05; Figure 6A ). In contrast, in the castrated group, which was without hypertension, there was no evidence of ventricular hypertrophy after Ang II infusion Downloaded from https://academic.oup.com/biolreprod/article-abstract/100/1/139/5068168 by OUP site access user on 18 March 2019 Figure 2 . Castration counteracts the hypertensive effect of Ang II, which was restored by testosterone. Intact, castrated and castrated with testosterone replaced rats were infused with Ang II or vehicle for 28 days, as described in Methods. Blood pressures were measured in the experimental groups before and during 28 days of Ang II infusion. Data are expressed as mean ± SEM.
* P < 0.05 Ang II vs vehicle, n = 6 for all experiments. Castration decreases AT1R/AT2R ratio in mesenteric arteries, which is restored by testosterone. Intact, castrated and castrated with testosterone-replaced rats were infused with vehicle or Ang II for 28 days as described in the Methods section. After the end of Ang II infusion, mesenteric arteries were removed and processed for western blotting. Representative western blots for AT1R and AT2R are shown at top; blot density obtained from densitometric scanning of AT1R and AT2R normalized to β-actin is shown at bottom. The ratio of AT1R/AT2R is presented. Values are given as means ± SEM of six rats in each group. * P < 0.05 compared with respective vehicle-infused group. # P < 0.05 compared with intact vehicle-infused group. § P < 0.05 compared with intact Ang II-infused group.
CAS-castrated, CAS+T-castrated with testosterone replacement.
(n = 6; Figure 6A ). In testosterone-replaced castrated males, Ang II induced increased ventricular weights identical to those of the intact group (n = 6; P < 0.05; Figure 6A ). These results suggest that Ang II infusion leads to cardiac hypertrophy in vivo in presence of testosterone. During hypertrophic cardiac remodeling, gene expression in myocardium undergoes characteristic alterations, including enhanced expression of ANP and fibrosis [41] . Previous studies have suggested that Ang II may stimulate these processes [42] . We therefore examined left ventricular mRNA expression of ANP and fibrosis. As shown in Figure 6B , Ang II infusion increased levels of ANP mRNA in hearts from in intact males (n = 6; P < 0.05). In contrast, Ang II-induced upregulation of ANP mRNAs was not detected in castrated males (n = 6; Figure 6B) . A similar pattern of Ang II induced upregulation was observed in testosterone replaced group as in the intact males (n = 6; P < 0.05; Figure 6B ).
Hearts from Ang II-infused intact males also displayed increased fibrosis, as indicated by Masson's trichrome staining (n = 3; P < 0.05; Figure 7 ). Castration alone had no effect but minimized Ang II-induced cardiac fibrosis (n = 3; Figure 7 ). Testosterone replacement in castrated males restored the ability of Ang II to induce fibrosis (n = 3; P < 0.05; Figure 7 ).
Discussion
The major findings of this study are testosterone, at physiologically relevant concentrations, leads to the development of Ang II-induced hypertension with associated increase in (1) the AT 1 R/AT 2 R ratio, and contractile response of mesenteric arteries to Ang II and phenylephrine; (2) left ventricle:body weight ratio and the expression of ANP mRNA in the left ventricle; and (3) fibrosis in the myocardium. A major finding in our study is that presence of testosterone is primarily responsible for the actions of Ang II to cause hypertension, vascular dysfunction, and cardiac hypertrophy since castration decreased plasma testosterone levels and also prevented Ang II-induced cardiovascular defects. Moreover, testosterone replacement in castrated rats restored the ability of Ang II to increase blood pressure and cardiac dysfunction to the same levels as in testes intact males. We suggest that the maintenance of higher AT 1 R/AT 2 R ratio in the vasculature by testosterone may contribute to androgenic potentiation of the hypertensive and vascular responses to Ang II in this model.
The development of hypertension is complex and is associated with the alteration of a wide range of systems. Sex steroid hormones, androgens, and estrogens are known to play an important role in blood pressure regulation. Men are generally at greater risk for CVD than are age-matched, premenopausal women. Experimental studies support the importance of sex hormones in blood pressure regulation by showing that either treatment with or absence of sex steroids alters the course of hypertension development [9, 10] . In the present study, chronic depletion of testosterone levels by castration abolished Ang II-induced blood pressure increase (mean decrease of 4 mmHg); however, the Ang II-induced hypertensive effect is greater in the males with intact testes (mean increase of 29 mmHg) and testosterone-replaced castrated males (mean increase of 28 mmHg). These findings show that testosterone is important in the hypertensive effect induced by Ang II as withdrawal (castration) prevented Ang II effects and replacement (testosterone) reversed the castration effects on Ang II-induced changes in blood pressure. This suggests that the development of Ang II-induced hypertension is androgen dependent, which appears to be similar to that observed in other in utero programming of increases in blood pressure [20, [43] [44] [45] .
The protective role of castration may not be directly related to the level of testosterone per se, but due to the testosterone withdrawal effect on other systems that control blood pressure. One potential mechanism for the protective status mediated by castration against Ang II-induced increase in blood pressure may involve modulation of Ang II receptor expression. Ang II acts through AT 1 R and AT 2 R. Increasing evidence has shown that AT 1 R is a key player for blood pressure increase [16, 46] . AT 2 R acts as a negative regulator of the vasoconstrictor effects of Ang II, and has an important blood pressure lowering effect [47] . It is suggested that when AT 1 R activity Figure 5 . Castration attenuates exaggerated mesenteric arterial contractile responses, which is restored by testosterone. Intact, castrated, and castrated with testosterone-replaced rats were infused with vehicle or Ang II for 4 weeks as described in the Methods section. After the end of Ang II infusion, mesenteric arteries were removed and processed for wire myography. Contractile responses were taken to cumulative additions of (A) Ang II, and (B) phenylephrine. Ang II and phenylephrine contractions are presented as percentage of 80 mM KCl contractions. Values are given as means ± SEM. n = 6 for all experiments. Figure 6 . Castration prevents Ang II-induced cardiac hypertrophy, which is restored by testosterone. Intact, castrated, and castrated with testosterone-replaced rats were infused with vehicle or Ang II for 28 days as described in the Methods section. After the end of Ang II infusion, heart was removed and weighed. (A) Mean left ventricle-to-body weight ratios, and (B) expression of ANP mRNA in left ventricle. Real-time PCR was used to assess ANP mRNA expression. Quantitation of ANP expression was normalized relative to GAPDH. Data are expressed as mean ± SEM of n = 6 for all experiments.
* P < 0.05 compared with respective vehicle-infused group. § P < 0.05 compared with intact Ang II-infused group. CAS-castrated, CAS+T-castrated with testosterone replacement.
is greater than AT 2 R, vasoconstriction to Ang II will predominate and hypertension will be induced [7, 29, 48] . Since testosterone is shown to regulate AT 2 R protein levels in the aorta of rat [20] , we determined whether mesenteric arterial AT 1 R and AT 2 R expression were altered in response to castration. Castration induced a significant decrease in AT 1 R and increase in AT 2 R protein expression, and this effect was restored by testosterone replacement. Thus, in intact and testosterone-replaced castrated males, the constitutive high levels of AT 1 R and lower AT 2 R with higher ratio of AT 1 R/AT 2 R may be important in maintaining the normal physiological and biological effects of Ang II. Loss of testosterone by castration decreased the vasoconstrictor AT 1 R and increased the vasodilator AT 2 R (i.e., decreased AT 1 R/AT 2 R ratio), yet there were no difference in blood pressure in the castrated rats compared to intact rats at basal state.
The reason for this is in unclear but possibly compensatory systems are activated to maintain blood pressure at physiological levels. The important finding is that decreased AT 1 R/AT 2 R ratio in castrated rats negated the Ang II effects to increase blood pressure, which is consistent with the studies that indicate AT 1 R/AT 2 R ratio plays a crucial role in the development of the hypertensive phenotype, and the vascular AT 1 R/AT 2 R ratio relates to the magnitude of blood pressure elevation observed in hypertensive rats [7, 29, 48] . Therefore, the protection against Ang II-induced increase in blood pressure in castrated rats may reflect alterations in the Ang II receptors systems, which are known to play an important role in longterm control of arterial pressure. Indeed, studies show that chronic blockade of AT 1 R or activation of AT 2 R prevents development of hypertension [49] . Although, we have shown that testosterone can Figure 7 . Castration minimizes Ang II-induced cardiac fibrosis, which is restored by testosterone. Intact, castrated and castrated with testosterone-replaced rats were infused with vehicle or Ang II for 4 weeks as described in the Methods section. After the end of Ang II infusion, heart was removed and processed for immunohistochemistry. Masson trichrome staining revealed intracardiac collagen deposition (intense blue staining). Photomicrographs are representative images of at least three animals from each experimental group. Presented below is the percentage of total fibrosis area as calculated as the summed bluestained areas divided by total ventricular area. * P < 0.05 compared with respective vehicle-infused group. § P < 0.05 compared with intact Ang II-infused group.
directly downregulate vascular AT 2 R through an androgen-receptormediated ERK1/2 MAP kinase pathway [20] , how testosterone modulates to increase the expression of AT 1 R need to be evaluated in future investigations. It is also important to note that Ang II, by itself also regulates its own receptors [50, 51] ; however, this study shows that presence of testosterone may potentiate the ability of Ang II to regulate its receptor. Increased peripheral vascular reactivity has been linked to the development and maintenance of hypertension [52] . In particular, enhanced peripheral vascular reactivity to Ang II has been identified in the spontaneously hypertensive rats [53] and prehypertensive humans [54] . To dissect out the functional effect of alterations in AT 1 R/AT 2 R ratio and the contribution of the peripheral vasculature to contractile responses and to blood pressure increase, we examined vascular reactivity to Ang II in mesenteric arteries. In the present study, Ang II-induced contractile responses were significantly increased in intact and testosterone-replaced castrated rats. The E max were greater in the Ang II-infused intact and testosterone-replaced rats, but was prevented by castration in proportion with the decreased AT 1 R/AT 2 R ratio and blood pressure decreases. Such data are consistent with classical receptor theory which predicts that increasing the contractile receptor number will result in an increase of the maximal responsiveness to agonists [55] . Other studies also reported testosterone-dependent exaggerated vasomotor responses to Ang II in growth-restricted offspring [29, 56] , genetically hypertensive rats [57] and testosterone-treated pregnant rats [31] . Interestingly, the vasomotor response to another vasoconstrictor, phenylephrine, was also enhanced in Ang II-infused intact and testosteronereplaced rats, but was prevented in castrated rats. Thus, it is likely that androgen potentiation of contractile effect may occur for multiple vasoconstrictors reflecting alterations not only occur at the receptor level, but at a common intracellular signaling level. Consistently, testosterone is shown to upregulate RhoA [58] , Rho kinase [59] , and PKC [57, 60] , which are important second messenger systems that amplifies the vascular smooth muscle contractile sensitivity.
Although we focused on the peripheral vascular reactivity, it is important to acknowledge that protection against Ang II-induced blood pressure increases in castrated rats may have a contribution from activation of brain [61] , kidney [62] and immune cells [63] . Similarly, testosterone metabolites, 6β-hydroxytestosterone and dihydrotestosterone are known players in mediating vascular and cardiac dysfunction [26] , hence it is possible that a component of Ang II-induced increase in arterial pressure be due to formation of these metabolites. It is also possible that the effect of androgens to facilitate Ang II actions is mediated via genomic or nongenomic androgen receptor [64] . However, restoration by testosterone of Ang II actions in castrated males was not due to alterations in expression of androgen receptor because expression of androgen receptor was not altered in these rats.
A major goal of hypertension treatment is to prevent or ameliorate injury to key target organs, including the heart. One of the most prevalent manifestations of end-organ damage in hypertension is the development of left ventricular hypertrophy and fibrosis [37] , and its presence confers substantial cardiovascular risk [37, 38] . Although pressure load from elevated blood pressure clearly contributes to left ventricular hypertrophy and fibrosis, several lines of evidence suggest that activation of the RAS also plays a role. For example, Ang II, acting through AT 1 R, stimulates hypertrophy of cardiac myocytes and interstitial fibrosis [65, 66] . In addition, clinical studies have demonstrated RAS blockage cause regression of cardiac hypertrophy and fibrosis more effectively than other classes of antihypertensive agents with similar levels of blood pressure control [39, 40, 67] . Thus, in this study it is difficult to distinguish whether the restoration of Ang II-induced cardiac remodeling in castrated males is due to direct cardiac Ang II receptor activation or secondary to restoration of blood pressure. However, the finding that the effects of Ang II were restored by testosterone replacement in castrated rats suggests that androgens play a permissive role in the development of Ang II-induced hypertension and associated cardiac effects.
In conclusion, this study demonstrates that testosterone play a permissive role in development and maintenance of Ang IIinduced hypertension, increased vascular reactivity to vasoconstrictor agents, cardiac hypertrophy and fibrosis. Modulation of ratio of AT 1 R/AT 2 R in the vasculature may be one mechanism critical to normalization of blood pressure in castrated males. Recently, the effect of sex chromosome complement has been implicated in Ang IIinduced hypertension [68] . Therefore, it appears that, in addition to sex chromosomes, testosterone contributes to Ang II-induced hypertension and associated pathogenesis in males. Identifying agents that prevent androgen-mediated upregulation of Ang II-induced hypertension could be useful for treatment of hypertension and associated CVD.
